These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 15877725)
21. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
22. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Aben KK; Luth TK; Janssen-Heijnen ML; Mulders PF; Kiemeney LA; van Spronsen DJ Eur J Cancer; 2008 Aug; 44(12):1701-9. PubMed ID: 18502115 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Passalacqua R; Buti S; Tomasello G; Longarini R; Brighenti M; Dalla Chiesa M Expert Rev Anticancer Ther; 2006 Oct; 6(10):1459-72. PubMed ID: 17069530 [TBL] [Abstract][Full Text] [Related]
24. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy? Kobayashi T; Nakamura E; Ogura K; Ogawa O BJU Int; 2005 Oct; 96(6):916. PubMed ID: 16153232 [No Abstract] [Full Text] [Related]
26. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Pantuck AJ; Belldegrun AS; Figlin RA Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295 [TBL] [Abstract][Full Text] [Related]
27. Conclusion and future directions. Samlowski WE; Vogelzang NJ Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339 [TBL] [Abstract][Full Text] [Related]
28. Management of metastatic renal cell carcinoma: current trends. Mohammed A; Shergill I; Little B Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350 [TBL] [Abstract][Full Text] [Related]
32. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Kuczyk M; Wegener G; Jonas U Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136 [TBL] [Abstract][Full Text] [Related]
33. Re: Capitanio et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. (Urology 2008;72:1090-1095). Chung SD; Chu SH; Tsai CC Urology; 2009 Mar; 73(3):682-3; author reply 683-4. PubMed ID: 19248907 [No Abstract] [Full Text] [Related]